Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trikafta Extension in Cystic Fibrosis
NCT04362761Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- May 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of elexacaftor + tezacaftor + ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) at 86 weeks. Started May 2020; status: completed.
02
Drugs
elexacaftor + tezacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT04362761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04362761.